Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
D000067956:Adenylyl Cyclase Inhibitors; D000661:Amphetamine; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001519:Behavior / Q000502:physiology; D001921:Brain / Q000378:metabolism*; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism* / Q000502:physiology; D018492:Dopamine Antagonists; D006801:Humans; D008032:Limbic System / Q000502:physiology; D011605:Psychoses, Substance-Induced / Q000378:metabolism; D011954:Receptors, Dopamine / Q000187:drug effects; D012154:Reticular Formation / Q000503:physiopathology; D012559:Schizophrenia / Q000378:metabolism* / Q000503:physiopathology; D013569:Synapses / Q000378:metabolism
D000067956:Adenylyl Cyclase Inhibitors; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D000661:Amphetamine; D004298:Dopamine